Eli Lilly looks attractively valued, with P/E ratios well below historical averages and robust momentum in Zepbound and ...

Eli Lilly stock is down 5% this month despite strong Q2 results and raised guidance, as data from a study on the obesity pill ...

The company said it was reviewing Mounjaro pricing with other governments and expected to make similar adjustments in certain ...

Eli Lilly, the maker of the popular injectable Mounjaro, has just released the surprising phase 3 trial results for its new ...

Lilly to raise UK Mounjaro price 170% from £122 to £330 monthly amid White House push for European drug price increases to ...

Price hikes are 'kick in the teeth' for patients who will either have to swallow 170 per cent price increase, or switch to ...

U.S. District Judge Karen Marston, of the Eastern District of Pennsylvania, allowed some misrepresentation claims to go ...

Ozempic sales have risen five-fold after a 126 per cent rise in the price of the Mounjaro drug due to pressure from US ...

Eli Lilly and Company (NYSE:LLY) is one of the Oversold Fundamentally Strong Stocks to Buy Now. On July 30, the company ...

Eli Lilly is planning to significantly hike the price of the weight-loss drug Mounjaro in the United Kingdom in a bid to make it cheaper in the U.S.

The launch marked Danish drugmaker Novo Nordisk's debut on the continent, ramping up competition with rival Eli Lilly.

Viking Therapeutics offers a speculative opportunity, driven by its promising obesity drug pipeline. Click here to read more ...